Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Fineline Cube Jan 13, 2026
Company Drug

Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China

Fineline Cube Jan 9, 2024

Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...

Company Medical Device

ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification

Fineline Cube Jan 9, 2024

ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper...

Company Drug

Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...

Company Drug

Thederma’s TAP-1503 Cream Receives Priority Review Status for Pediatric Atopic Dermatitis Treatment in China

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Thederma’s TAP-1503 cream is...

Company Drug

Innovent Biologics’ Mazdutide Achieves Positive Results in Phase III Clinical Trial for Overweight or Obesity

Fineline Cube Jan 9, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Deals

Bain Capital-Backed Tenacia Strikes Deal with Praxis Precision Medicines for Essential Tremor Treatment

Fineline Cube Jan 9, 2024

Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital, has entered into an...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment

Fineline Cube Jan 9, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Company Drug

Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP

Fineline Cube Jan 9, 2024

Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S.,...

Company Deals

Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology

Fineline Cube Jan 9, 2024

Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in...

Company Deals

Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine

Fineline Cube Jan 9, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Drug

CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Deals

Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders

Fineline Cube Jan 9, 2024

Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow...

Company Drug

Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017

Fineline Cube Jan 9, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced...

Company

WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility

Fineline Cube Jan 9, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for Phase Ib/II Study of SHR-A1921 Combo in Advanced Solid Tumors

Fineline Cube Jan 9, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

Biocytogen Strikes Exclusive Licensing Deal with US-Based Radiance Biopharma for Innovative BsADC

Fineline Cube Jan 9, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a leading biopharmaceutical company based in China ,...

Company Drug

MSD Advances Four Oncology Candidates to Late-Stage Trials, Including Partnerships with Kelun-Biotech and Orion

Fineline Cube Jan 8, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced significant progress in its oncology pipeline...

Company Deals

AstraZeneca Secures Exclusive Rights to Omniose’s Enzyme Platform for Bacterial Vaccine Development

Fineline Cube Jan 8, 2024

AstraZeneca (AZ; NASDAQ: AZN) has secured an exclusive licensing agreement with biotechnology firm Omniose for...

Company Policy / Regulatory

China’s NHSA Aims to Balance Drug Prices with New Monitoring System by March 2024

Fineline Cube Jan 8, 2024

The National Healthcare Security Administration (NHSA) has issued a notification aimed at fostering inter-provincial price...

Company Deals

AbbVie Partners with Umoja Biopharma to Develop Next-Generation CAR-T Therapies

Fineline Cube Jan 8, 2024

AbbVie (NYSE: ABBV) has entered into a collaboration agreement with Umoja Biopharma, a US-based company...

Posts pagination

1 … 361 362 363 … 609

Recent updates

  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
  • Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
  • ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.